March 29, 2023

Senator Bernie Sanders
Chairman
Senate Committee on Health, Education, Labor and Pensions
Washington, D.C. 20510

Senator Bill Cassidy, M.D.
Ranking Member
Senate Committee on Health, Education, Labor and Pensions
Washington, D.C. 20510

Re: Comments in Response to PAHPA Request for Information

Sent to: PAHPA2023Comments@help.senate.gov

Dear Chairman Sanders and Ranking Member Cassidy:

The College of American Pathologists (CAP) appreciates the opportunity to provide feedback and suggestions in response to the Committee’s request for information (RFI) that should be considered during the reauthorization process of the Pandemic and All-Hazards Preparedness Act (PAHPA). The CAP is the world’s largest organization of board-certified pathologists and the leading provider of laboratory accreditation and proficiency testing programs. The CAP serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. As you are aware, pathologists are physicians who specialize in the diagnosis of disease. The expertise they provide drives treatment decisions that optimize outcomes for patients. During the COVID-19 public health emergency, pathologists were on the frontline of the crisis. They were responsible for ensuring prompt and accurate testing for patients and health care providers alike.

The battle against COVID-19 highlighted critical areas of concern that must be addressed to better prepare for future pandemics. As such, the CAP offers the following recommendations for consideration during the PAHPA reauthorization process. Specifically, the CAP urges the Committee to:

- Consider policies to standardized electronic laboratory reporting and authorize funding to enhance lab information systems;
- Strengthen the supply chain;
- Ensure a mechanism for adequate coverage and reimbursement of tests during a public health emergency (PHE); and
- Authorize funding to strengthen the laboratory workforce.

Consider Policies on Electronic Lab Reporting and Authorize Funding to Enhance Laboratory Information Systems

The CAP believes more should be done to establish a uniform and standardized system for data sharing with public health agencies, and that Congress should ensure that burdens on data providers are manageable and streamlined given the critical role that such providers play during a PHE. The
current pandemic highlighted the need for standardized data reporting to public health agencies for
officials to access comprehensive and nearly real-time data to inform decision making in their
response during the PHE. As such, the **CAP supports the creation of national standardized
minimum data reporting requirements and formats in which clinical laboratories would be
required to report only to the state in which the laboratory is located. The minimum data
required to be reported should include only those data typically available to clinical
laboratories.** The same national standards could be used by state public health agencies to report
data on out-of-state patients to the state public health agency of the patient’s residency.
Alternatively, the federal government could establish a national data hub for public health, during a
PHE, for use in distributing public health-related results to various locations in a standardized format.

During the pandemic, laboratories reported disparate, burdensome, and uneven data reporting
requirements. Despite the high percentage of electronic health record (EHR) adoption (80% of
physician offices with certified EHRs and 93% of small rural critical access hospitals with EHRs),
laboratories continue to receive paper requisitions because 1) the EHR does not have an electronic
interface with the laboratory performing the test, 2) the EHR has an interface but does not have this
particular test in its catalog of tests, and least commonly 3), the EHR is in a downtime. Regarding the
first reason, electronic interfaces are expensive to implement and maintain, and for this reason, it is
not possible for an EHR to have interfaces with all laboratories that may perform testing. Even where
electronic interfaces do exist, clinical laboratories still often receive inadequate demographic and
other clinical information requested by some public health laboratories and government agencies.
Additionally, paper requisitions often lack adequate patient demographic information, regardless of
whether the orders are billed to an insurer or third-party, rather than to patients. Consequently,
addressing national standards for orders through EHR changes may not result in better data
collection because laboratories will continue to have challenges when receiving paper orders and the
barrier of the cost of interfacing with each ordering facility.

The requirements imposed by HHS for additional public health reporting during the pandemic
created significant strain on laboratories’ financial and human resources at a time when they were
already stretched beyond limit. The electronic submission of laboratory results to public health
agencies is not currently mandated at the federal level, and states vary on whether electronic
submission is required and on the format of the electronic submission. Each interface with an EHR or
with an individual state’s public health agency is costly ($40,000 to $70,000 on average per
interface), and each change made to an interface also has associated costs. Further complicating
the matter is the variability by states as to who is required to do the reporting, which further supports
the need for national minimum standards.

Better coordination at the federal and state levels and funding for laboratories to purchase and/or
enhance laboratory information systems would improve data collection and strengthen our nation’s
response to public health crises. **More specifically, federal funding should be made available to
laboratories to fully cover the costs of installation, validation, maintenance, and any required
updates of electronic public health reporting software and interfaces, as the nation’s**
laboratories cannot continue to absorb these “unfunded mandates” during future PHEs. Ultimately, it is the responsibility of HHS and state (and local) agencies to develop and adopt uniform standards and common pathway solutions for reporting and sharing all public health data (and not limited to a PHE), to prevent this unreasonable burden on laboratories or other required reporting entities from occurring again.

**Strengthen the Supply Chain**
The CAP applauds Congress for passing the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT) Pandemics Act. However, the CAP believes additional work is needed. As such, the CAP urges the Committee to clarify that clinical laboratory testing capacity is a critical part of the supply chain. The PREVENT Pandemics Act authorizes HHS to contract directly with domestic manufacturers to ensure reserve manufacturing capacity for important medical products. The CAP believes that the Committee should clarify that this authority expressly authorizes the HHS to contract directly with clinical laboratories, including small and medium size laboratories, to ensure reserve testing capacity.

**Ensure a Mechanism for Adequate Coverage and Reimbursement of Tests During a PHE**
The CAP believes the Committee has an opportunity to address coverage and payment of tests during the reauthorization of PAHPA. The rapid establishment of medical billing codes, coverage, and national payment rates is essential to ensuring robust provider and patient access to tests. And while expedited processes for coding are established, the U.S. lacks a durable policy to rapidly develop comprehensive coverage and payment to private-sector testing partners.

For example, during the pandemic, the Medicare reimbursement rates for COVID-19 tests did not adequately reflect the cost associated with providing the tests and the established processes to determine these clinical laboratory test prices were not followed. The payment rates were set without access to costs and charges for the test, and the Medicare Administrative Contractors (MAC) never revealed the methodology they used to establish payment. The cost of the reagents, supplies, and clinical labor involved to provide one of these tests, as well as the incremental equipment and other fixed capital costs, far exceeded the MAC reported payment amounts. Many supplies and clinical labor were reported to be in erratic and short supply, resulting in higher costs for all producers.

All the laboratory cost managers we interviewed during the pandemic indicated their laboratory had to have multiple testing platforms as they struggled to keep up with the demand for testing. The multiple platforms provided some flexibility for the continuous erratic availability of reagent and other supplies. As one laboratory platform runs low or out of supplies, others are used and brought online until needed supplies are obtained. Laboratories purchased new equipment, set up the equipment, developed protocols, proficiency tests, obtained new supply chains, trained clinical staff, ran the tests, and maintained them. Some laboratory cost managers also reported when there were insufficient testing capabilities, they also sent the tests out to large laboratories for analysis, adding an additional layer of costs and delays in test reporting. Significant costs were incurred across the country as laboratories struggled with the crisis the best they could.
Inappropriately low-test pricing leads to unnecessary delays and complications in any crisis. During the pandemic, large, medium, and small hospital laboratories were highly involved in providing COVID-19 tests. In fact, our survey found that medium-sized hospital labs accounted for 2/3 of labs providing molecular COVID-19 testing.

The reimbursement rates for COVID-19 tests ranged from $35 to $100, but those rates failed to account for the costs and resources necessary to bring testing online during the national public health crisis for laboratories of all sizes and localities. The rates favored large, high volume testing providers while economically disadvantaging many frontline and primary testing providers in small, medium sized, and acute care hospital and academic laboratory settings who were responsible for rapidly identifying and caring for COVID-19 patients during the pandemic. These frontline providers were forced to diversify and develop multiple and expensive testing methods and manage different combinations of analytical platforms to address the unprecedented shortages and unmet demands for expanded and more accessible SARS-CoV-2 testing in their local communities. It is critical that the established Medicare processes to determine clinical laboratory test prices are followed in the future and appropriate pricing is secured going forward.

During the COVID-19 public health emergency, the CAP had also requested immediate national coverage for multiplex polymerase chain reaction (PCR) respiratory viral panel (RVP) tests and recommended that the CMS remove local coverage barriers and provide uniform national coverage for the clinical diagnostic laboratory tests that may be performed without a practitioner order. Providers needed the ability to rapidly identify the pathogen causing the patient’s symptoms to ensure they were in fact COVID-19 negative, and then appropriately isolate or cohort a patient accordingly. Many respiratory pathogens presented similarly in patients, and it was difficult to differentiate between influenza, coronavirus, rhinoviruses, and many other pathogens without accurate testing. Ensuring rapid results with uniform coverage policies would have helped triage patients and minimize disease transmission during the pandemic. Therefore, the CAP urges the Committee to consider policies to establish mechanisms to ensure adequate coverage and reimbursement of tests during a PHE.

**Authorize Funding to Strengthen the Laboratory Workforce**

Finally, to ensure the health of the nation’s diagnostics infrastructure, policymakers should take steps to strengthen our nation’s laboratory workforce. Laboratory professionals, the physician and non-physician workforce, are critical to efforts to identify and remediate the spread of infectious diseases, such as COVID-19. They perform approximately 13 billion laboratory tests each year, the single highest-volume medical activity affecting Americans’ healthcare. The information these professionals provide is essential for patients to receive safe, effective, and efficient care from their providers. Recent surveys of physicians estimate that 60-70% of medical decisions regarding a patient’s diagnosis and/or treatment are impacted by laboratory test results.
Unfortunately, like the physician shortage which the CAP recently submitted comments on, many laboratories currently suffer from personnel shortages and are operating at or near crisis-mode. Student loan debt for healthcare professionals is $10,000 more than for any other profession. The educational costs borne by health professionals also pose a considerable barrier to career entry for many underrepresented minority students, whose economic resources tend to be less than those of other students. Non-physician medical laboratory professionals are generally not eligible for federal workforce development programs. Therefore, the CAP urges the Committee to consider the following proposals to strengthen the laboratory workforce during the reauthorization of PAHPA:

- Fund and expand eligibility for federal scholarship, fellowship, and loan repayment programs;
- Utilize federal resources to raise the visibility of careers like laboratory medicine with support of career fairs, public service announcements, etc. Programs like the Centers for Disease Control and Prevention OneLabVR, for example, could be utilized at school career fairs to educate students about medical laboratory and other careers;
- Provide funding to increase the availability and capacity of accredited laboratory training programs;
- Incentivize service as medical laboratory faculty by increasing funding for the Faculty Loan Repayment Program; and
- Expand the National Health Service Corps Scholarship Program to include laboratory personnel.

In closing, the CAP appreciates the opportunity to respond to the PAHPA RFI. Should you have questions please contact Darren Fenwick at dfenwic@cap.org.

Sincerely,

Emily E. Volk, MD, FCAP
President